Literature DB >> 18193277

Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.

Alexander Schipf1, Doris Mayr, Thomas Kirchner, Joachim Diebold.   

Abstract

The origin of carcinosarcomas of the ovary and uterus has long been discussed. In this study, we used a molecular-genetic approach to elucidate the tumorigenesis of carcinosarcomas of these organs correlating our findings with the specific biphasic pattern of these tumors. We analyzed a series of 30 paraffin-embedded carcinosarcomas of the ovary and the uterus using comparative genomic hybridization (CGH) and fluorescence in-situ hybridization (FISH). In general, gains (85%) were observed more frequently, than losses (30%). Characteristic and frequent chromosomal amplification was observed on chromosome 8q and 20q (42 and 70%). FISH revealed c-myc (8q24.12) and ZNF217 (20q13.2) amplification in 78 and 87%. Amplification of ZNF217 was mostly seen in both tumor components, whereas amplification of c-myc was observed less often in the sarcomatous than in the carcinomatous tumor component. Analysis of the proliferation index using Ki67 immunohistochemistry revealed a strong or moderate expression in all cases, wherein the carcinomatous tumor component showed significantly a higher proliferation index compared to the sarcomatous tumor areas. Although our results are in agreement with a monoclonal origin of ovarian and uterine carcinosarcomas, the carcinomatous component seems to be the more aggressive part of the tumor. Furthermore, the observed patterns of genetic aberrations are highly similar to those of serous carcinomas. This is compatible with the current opinion that these neoplasms should be considered as metaplastic carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18193277     DOI: 10.1007/s00428-007-0557-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  39 in total

1.  Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis.

Authors:  L Thompson; B Chang; S H Barsky
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

2.  Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements.

Authors:  M Emoto; H Iwasaki; M Ishiguro; M Kikuchi; S Horiuchi; T Saito; N Tsukamoto; T Kawarabayashi
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

3.  p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): a clinicopathologic study of 74 cases.

Authors:  M J Costa; J Vogelsan; L J Young
Journal:  Mod Pathol       Date:  1994-08       Impact factor: 7.842

4.  Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.

Authors:  R Blom; C Guerrieri; O Stâl; H Malmström; S Sullivan; E Simonsen
Journal:  Gynecol Oncol       Date:  1998-01       Impact factor: 5.482

5.  Ultrastructure of mesodermal mixed tumor of the uterus.

Authors:  S Ishikawa; H Kaneko; T Sumida; M Sekiya
Journal:  Acta Pathol Jpn       Date:  1979-09

6.  Genomic aberrations in carcinomas of the uterine corpus.

Authors:  Francesca Micci; Manuel R Teixeira; Lisbeth Haugom; Gunnar Kristensen; Vera M Abeler; Sverre Heim
Journal:  Genes Chromosomes Cancer       Date:  2004-07       Impact factor: 5.006

7.  Establishment and characterization of carcinosarcoma cell line of the human uterus.

Authors:  I Gorai; C Doi; H Minaguchi
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

8.  Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed müllerian tumors). Clinicopathologic study of 82 cases.

Authors:  M J Costa; J Walls
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

9.  Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases.

Authors:  P A de Brito; S G Silverberg; J M Orenstein
Journal:  Hum Pathol       Date:  1993-02       Impact factor: 3.466

10.  Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma.

Authors:  C Collins; J M Rommens; D Kowbel; T Godfrey; M Tanner; S I Hwang; D Polikoff; G Nonet; J Cochran; K Myambo; K E Jay; J Froula; T Cloutier; W L Kuo; P Yaswen; S Dairkee; J Giovanola; G B Hutchinson; J Isola; O P Kallioniemi; M Palazzolo; C Martin; C Ericsson; D Pinkel; D Albertson; W B Li; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  15 in total

1.  Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.

Authors:  Gloria S Huang; Marc J Gunter; Rebecca C Arend; Maomi Li; Hugo Arias-Pulido; Eric R Prossnitz; Gary L Goldberg; Harriet O Smith
Journal:  Am J Obstet Gynecol       Date:  2010-06-03       Impact factor: 8.661

Review 2.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 3.  Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Authors:  T S Shylasree; Andrew Bryant; Ram Athavale
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Molecular profiling of endometrial malignancies.

Authors:  Norasate Samarnthai; Kevin Hall; I-Tien Yeh
Journal:  Obstet Gynecol Int       Date:  2010-03-28

5.  A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Authors:  Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2014-03-01       Impact factor: 5.482

Review 6.  [Serous ovarian tumors].

Authors:  J Diebold
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

7.  Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.

Authors:  Rhoda Raji; Federica Guzzo; Luisa Carrara; Joyce Varughese; Emiliano Cocco; Stefania Bellone; Marta Betti; Paola Todeschini; Sara Gasparrini; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter Schwartz; Thomas J Rutherford; Natalia Buza; Sergio Pecorelli; Alessandro D Santin
Journal:  J Exp Clin Cancer Res       Date:  2011-11-10

8.  Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Authors:  Lauren Patterson Cobb; Stephanie Gaillard; Yihong Wang; Ie-Ming Shih; Angeles Alvarez Secord
Journal:  Gynecol Oncol Res Pract       Date:  2015-05-12

9.  Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.

Authors:  Jun Zhu; Hao Wen; Rui Bi; Xiaohua Wu
Journal:  J Gynecol Oncol       Date:  2015-10-12       Impact factor: 4.401

10.  The biology of uterine sarcomas: A review and update.

Authors:  Hiroshi Kobayashi; Chiaki Uekuri; Juria Akasaka; Fuminori Ito; Aiko Shigemitsu; Natsuki Koike; Hiroshi Shigetomi
Journal:  Mol Clin Oncol       Date:  2013-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.